Elon’s New Device is About to Shock the World

Using this device you see above… Elon Musk just tested a new type of A.I. that according to Wired Magazine will usher in… “The next step in human evolution.”

Click here to see the details because there’s a lot of money at stake.

Pascal Deschatelets net worth and biography

Pascal Deschatelets Biography and Net Worth

Insider of Apellis Pharmaceuticals

Dr. Deschatelets co-founded Apellis Pharmaceuticals in November 2009 and joined as its chief scientific officer. Prior to founding Apellis, Dr. Deschatelets co-founded Potentia Pharmaceuticals and was its chief operating officer when the company signed a licensing agreement with Alcon in 2009 for Potentia’s ocular drug development program. Apellis acquired all of the assets of Potentia in a transaction that closed in September 2015. Dr. Deschatelets has been engaged in state-of-the-art research in the areas of surface chemistry and organic synthesis for the last 25 years, and he was a co-founder of Syntetica Fine Chemicals, a custom chemical synthesis company supporting the pharmaceutical industry. He has extensive experience in nanobiotechnology and in the synthesis of organic molecules and bioconjugates. Dr. Deschatelets received his PhD degree in organic chemistry from the University of Montreal and his postdoctoral training in the laboratory of Dr. George Whitesides at Harvard University.

What is Pascal Deschatelets' net worth?: The estimated net worth of Pascal Deschatelets is at least $47.21 million as of April 8th, 2024. Dr. Deschatelets owns 1,115,983 shares of Apellis Pharmaceuticals stock worth more than $47,206,081 as of May 8th. This net worth approximation does not reflect any other assets that Dr. Deschatelets may own. Learn More about Pascal Deschatelets' net worth.
How do I contact Pascal Deschatelets?: The corporate mailing address for Dr. Deschatelets and other Apellis Pharmaceuticals executives is 100 FIFTH AVENUE, WALTHAM MA, 02451. Apellis Pharmaceuticals can also be reached via phone at (617) 977-5700 and via email at [email protected]. Learn More on Pascal Deschatelets' contact information.
Has Pascal Deschatelets been buying or selling shares of Apellis Pharmaceuticals?: In the last ninety days, Pascal Deschatelets has sold $3,743,526.19 in Apellis Pharmaceuticals stock. Most recently, Pascal Deschatelets sold 69,107 shares of the business's stock in a transaction on Monday, April 8th. The shares were sold at an average price of $54.17, for a transaction totalling $3,743,526.19. Following the completion of the sale, the insider now directly owns 1,115,983 shares of the company's stock, valued at $60,452,799.11. Learn More on Pascal Deschatelets' trading history.
Who are Apellis Pharmaceuticals' active insiders?: Apellis Pharmaceuticals' insider roster includes Caroline Baumal (Insider), Victoria Brown (Insider), James Chopas (CAO), Mark DeLong (SVP), Pascal Deschatelets (Insider), A. Dunlop (Director), Jeffrey Eisele (Insider), Cedric Francois (CEO), Federico Grossi (Insider), Karen Lewis (Insider), Alec Machiels (Director), Nur Nicholson (Insider), Nicole Perry (VP), Lukas Scheibler (Insider), Timothy Sullivan (CFO), Adam Townsend (Insider), and David Watson (General Counsel). Learn More on Apellis Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Apellis Pharmaceuticals?: During the last twelve months, insiders at the sold shares 54 times. They sold a total of 827,985 shares worth more than $50,786,201.25. The most recent insider tranaction occured on April, 8th when insider Pascal Deschatelets sold 69,107 shares worth more than $3,743,526.19. Insiders at Apellis Pharmaceuticals own 7.5% of the company. Learn More about insider trades at Apellis Pharmaceuticals.
Information on this page was last updated on 4/8/2024.

Pascal Deschatelets Insider Trading History at Apellis Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
4/8/2024	Sell	69,107	$54.17	$3,743,526.19	1,115,983
11/8/2023	Sell	12,000	$47.27	$567,240.00	1,071,807
10/9/2023	Sell	12,000	$40.38	$484,560.00	1,066,313
9/8/2023	Sell	12,000	$42.87	$514,440.00	1,059,813
8/8/2023	Sell	12,000	$23.66	$283,920.00	1,053,313
7/10/2023	Sell	12,000	$84.55	$1,014,600.00	1,046,813
6/8/2023	Sell	12,000	$91.35	$1,096,200.00	1,040,313
5/8/2023	Sell	12,000	$92.39	$1,108,680.00	1,033,813
4/10/2023	Sell	12,000	$78.21	$938,520.00	1,027,313
3/8/2023	Sell	12,000	$63.79	$765,480.00	1,020,813
2/8/2023	Sell	12,000	$54.45	$653,400.00	1,006,756
1/9/2023	Sell	12,000	$46.08	$552,960.00	983,780
12/8/2022	Sell	12,000	$47.50	$570,000.00	970,280
11/8/2022	Sell	12,000	$46.47	$557,640.00	963,780
10/10/2022	Sell	12,000	$57.50	$690,000.00	957,280
9/8/2022	Sell	12,000	$63.98	$767,760.00	950,780
7/8/2022	Sell	12,000	$47.95	$575,400.00	937,780
6/8/2022	Sell	12,000	$44.09	$529,080.00	891,775
4/29/2022	Sell	4,000	$44.43	$177,720.00	891,775
6/24/2021	Sell	6,250	$65.61	$410,062.50	875,837
4/23/2021	Sell	6,250	$46.13	$288,312.50	871,337
3/10/2021	Sell	6,250	$50.74	$317,125.00
9/24/2019	Sell	42,460	$24.82	$1,053,857.20

Pascal Deschatelets Buying and Selling Activity at Apellis Pharmaceuticals

Apellis Pharmaceuticals Company Overview

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.

Today's Range

Now: $42.30

$41.57

$44.12

50 Day Range

MA: $54.74

$43.90

$64.63

2 Week Range

Now: $42.30

$19.83

$94.75

Volume

2,160,432 shs

Average Volume

1,579,954 shs

Market Capitalization

$5.13 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.97